PKM and pancreatic ductal adenocarcinoma: It was proposed that the tumors with increased background expression of PKM2 show a more aggressive phenotype and poor response to chemotherapy in pancreatic ductal adenocarcinoma patients undergoing radical surgery and adjuvant chemotherapy (100).